BioCentury
ARTICLE | Top Story

Halozyme, Pfizer in rHuPH20 biologics deal

December 22, 2012 1:33 AM UTC

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $1.49 (27%) to $7.01 on Friday after granting Pfizer Inc. (NYSE:PFE) worldwide rights to develop and commercialize products comprising undisclosed biolo...